Echo Bay Pharmaceuticals, LLC v. Torrent Pharma, Inc.

Background

Echo Bay Pharmaceuticals, LLC and Torrent Pharma, Inc. were parties to a Co-Development Settlement Agreement concerning generic pharmaceutical products. Torrent received exclusive worldwide commercialization rights and was responsible for development activities, while the parties generally shared development expenses. The agreement also allowed either party to stop contributing development expenses before Food and Drug Administration approval, with written notice; in certain circumstances, Echo Bay could continue developing and commercializing a product itself.

No drug application for the four products at issue received approval. Echo Bay alleged that Torrent mishandled development, failed to address problems at its manufacturing facility, stopped development activities, failed to pay half of a development-related invoice, and withdrew the Fluocinonide application without telling Echo Bay. Echo Bay asserted a single breach-of-contract claim based on alleged violations of express contract provisions and the implied duty of good faith and fair dealing.

Motion to dismiss

Torrent moved to dismiss under Federal Rule of Civil Procedure 12(b)(6), which allows dismissal when a complaint does not adequately state a legally plausible claim. The court applied New York contract law because both parties relied on it.

The court rejected Echo Bay’s claims based on the contract’s provisions requiring compliance with laws and regulations because the regulatory problems described in the complaint did not establish a violation involving the products covered by the agreement. It also ruled that the expense provisions did not require Torrent to reimburse expenses incurred by Echo Bay, and that the agreement did not guarantee successful development, profits, or a particular level of effort. The court therefore found that Echo Bay had not adequately pleaded breaches involving the development obligations, expense provisions, or other express terms.

The court also rejected Echo Bay’s proposed implied duty requiring Torrent to use reasonable efforts or to continue development. In the court’s view, such a duty would conflict with the agreement’s express provision allowing Torrent to stop contributing development expenses before approval.

Fluocinonide notice claim

The court treated the proposed implied notice obligation differently. It held that the implied duty of good faith and fair dealing may require notice when notice is necessary to protect an express contractual benefit. Echo Bay alleged that Torrent secretly withdrew the Fluocinonide application and concealed the withdrawal until after this lawsuit was filed. According to the court, those allegations plausibly suggested that Torrent prevented Echo Bay from timely exercising its contractual right to take over development and commercialization and deprived it of access to regulatory filings.

The court nevertheless found that Echo Bay had not adequately alleged damages caused by the lack of notice. Echo Bay needed to allege facts showing that, if it had received timely notice, it would have exercised its contractual rights, brought Fluocinonide to market, and earned a profit.

Disposition

Judge Barbara Moses granted Torrent’s motion to dismiss the Second Amended Complaint. The court granted leave to amend only for the claim that Torrent breached the implied duty of good faith and fair dealing by withdrawing the Fluocinonide application without notice, including a possible damages theory. The court directed Echo Bay to file its Third Amended Complaint within 30 days. The opinion did not allow amendment of the other dismissed theories.